CoChat

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Significance: Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer by 2030. Advances in therapeutic treatments are urgently required to fight against this fatal disease. Here, elucidation of the metabolic signature of PDAC has identified the low-density lipoprotein receptor (LDLR), which facilitates cholesterol uptake, as a promising therapeutic target. Blocking of LDLR reduces the proliferative and clonogenic potential of PDAC cells and decreases activation of the ERK1/2 survival pathway. Moreover, LDLR silencing sensitizes PDAC cells to chemotherapeutic drugs and potentiates the tumoral regression promoted by chemotherapy. Finally, Ldlr is highly expressed at all stages of human PDAC and expression is associated with an increased risk of PDAC recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1421601112

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 482

Metadata

Authors
Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., Pinault, M., Guimaraes, C., Nigri, J., Loncle, C., Lavaut, M.-N., Garcia, S., Tailleux, A., Staels, B., Calvo, E., Tomasini, R., Iovanna, J. L., & Vasseur, S.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • INSERM, UMR911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, F-13385 Marseille, France;
  • Université de Tours (FR)
  • Inserm (FR)
  • Molecular Endocrinology and Oncology Research Center, Quebec, QC, Canada G1V 4G2
Venue
Proceedings of the National Academy of Sciences
Published
2015-02-09
Volume
112
Issue
8
Pages
2473-2478
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1977773843
Cited by
454
References
31
Citations by year
2026: 31 · 2025: 40 · 2024: 48 · 2023: 55 · 2022: 59 · 2021: 62 · 2020: 47 · 2019: 25 · 2018: 30 · 2017: 24 · 2016: 23 · 2015: 8
FWCI
9.36
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation de France
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
pancreatic ductal adenocarcinoma, cholesterol absorption, LDL receptor, cancer metabolism, lipid metabolism, desmoplasia, chemosensitization, metabolic therapy, recurrence
MeSH terms
Gemcitabine, Adenocarcinoma, Animals, Cell Compartmentation, Cholesterol, Clone Cells, Deoxycytidine, Epithelial Cells, Humans, Lipoproteins, Pancreatic Neoplasms, Phenotype, Prognosis, Receptors, LDL, Up-Regulation, Gene Expression Regulation, Neoplastic, Gene Silencing, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. https://app.cochat.ai/papers/10.1073/pnas.1421601112
The paper
Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., Pinault, M., Guimaraes, C., Nigri, J., Loncle, C., Lavaut, M.-N., Garcia, S., Tailleux, A., Staels, B., Calvo, E., . . . Vasseur, S. (2015). Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1421601112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.